•  
  •  
 

Subject Area

Dermatology

Article Type

Original Study

Abstract

Objective To focus on the recent trends in the management of deep vein thrombosis (DVT) in malignancy as well as its fatal complications. Background DVT is usually silent in nature in most of the hospitalized patients and is usually presented by nonspecific symptoms and signs. Patients and methods A prospective study was carried out on 60 patients at Ahmed Maher Teaching Hospital between 2017 and 2018. The patients were divided into two groups: the first group composed of 30 cancer patients on whom prophylactic measures against venous thromboembolism was applied for 8 months and the second group composed of 30 cancer patients with a history of DVT and who had undergone management and follow-up for 3–6 months. Full history, routine, physical examination, routine investigations, and coagulation profile were done. Results The mean age of the prevention group was 54.87 ± 11.34 and 59.10 ± 12.50 in the management group. The incidence of DVT was 16.7%. In the management group, the rate of resolution of DVT without complications after being treated with low molecular weight heparin (LMWH) for 6 months was 66. The rate of cases developed pulmonary embolism from the management group was 10%. The rate of deaths due to DVT and its complications was 3.3%. Conclusion LMWH prophylaxis in patients undergoing cancer-related surgery has proved to be effective and safe in reducing the risk of an acute event. Thromboprophylaxis with LMWH, unfractionated heparin, and mechanical methods should be considered for all patients with a malignancy who undergo surgery.

Download

Share

COinS